Condition: Tuberculosis · Multidrug Resistant Pulmonary Tuberculosis · Rifampicin-resistant Tuberculosis · Sponsor: WestVac Biopharma Co., Ltd.
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Wuhan Pulmonary Hospital | Wuhan, Hubei, China | Recruiting |
| Changsha Central Hospital | Changsha, Hunan, China | Recruiting |
| The Second Hospital of Nanjing | Nanjing, Jiangsu, China | Recruiting |
| Shandong Public Health Clinical Center | Jinan, Shandong, China | Recruiting |
| Public Health Clinical Center of Chengdu | Chengdu, Sichuan, China | Recruiting |
| Beijing Chest Hospital, Capital Medical University | Beijing, China | Recruiting |
| Huashan Hospital Fudan University | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07170800